We herein report the case of a 3-year-old girl with atypical congenital right upper limb lymphedema who developed an angiosarcoma. Only a few cases have been reported following congenital form of lymphedema and only 4 in such a young child.
| INTRODUCTION
Stewart-Treves syndrome is a cutaneous secondary angiosarcoma occurring in a context of chronic lymphedema. Most commonly, it occurs after mastectomy or radiotherapy for breast cancer. More than 400 cases of Stewart-Treves syndrome have been reported but only 4 cases in association with congenital form of lymphedema before the age of 16 years. The first case was reported in 1918 by Kettle. 1, 2 The disease usually occurs after several years of evolution of chronic lymphedema with a mean interval of 9-11 years. The clinical presentation is heterogeneous, and the diagnosis is delayed from 2 months to over 3 years. 1, 2 The survival rate is low, and treatment options are limited.
We report herein the case of a 3-year-old girl with congenital atypical primary upper limb lymphedema associated with chylothorax, who developed diffuse and treatment-resistant angiosarcoma with fatal outcome. 
| CASE REPORT
A
| DISCUSSION AND CONCLUSION
Angiosarcoma is a rare and highly aggressive neoplasm, which arises from endothelium of lymphatic or blood vessels. Lymphangiosarcoma or Stewart-Treves syndrome is an angiosarcoma associated with acquired or congenital chronic lymphatic obstruction.
1,2
All ages combined only 24 cases have been described in association with congenital lymphedema (Tables 1 and 2 ). The mean age of onset was 33 years (range 2-85 years) and occurrence is predominantly in females (15/24). Presentation in childhood is very rare, with only 4 reported cases in patients younger than 16 years. Our patient is the fifth case ( Table 2 ). All 5 are girls.
Lymphatic malformations are due to dysgenesis of the lym- puberty. 3 Our patient was presented with atypical primary congenital lymphedema associated with bilateral chylous pleural effusion.
Thus, there could be an associated central conducting lymphatic
anomaly. Over 20 genes are known to be associated with various types of primary lymphedema. 4 None of the known genes for lymphedema were abnormal. However, in the biopsy of the (Table 1) . [5] [6] [7] [8] [9] Angiosarcoma associated with congenital chronic lymphedema affects the extremities, except for one case located in the genital area ( Table 1) . The four children with this disease were girls with involvement of the extremities, as our case (Table 2) . It most frequently (n = 12/24) presents as firm, palpable red to blue papules or nodules (Tables 1 and 2) . Clinical signs are similar in children ( The mainstay of treatment for angiosarcoma is surgical resection.
Among the 24 cases reported in the literature, more than 2 of 3 of the patients underwent amputation of the affected limb. Early amputation is the only treatment shown to prolong survival; however, long-term survival is rare. 10 Only 5 patients received adjuvant chemotherapy and 6 others adjuvant radiotherapy ( Table 1 ). Chemotherapy that has been reported in the treatment of angiosarcoma includes 5-fluorouracil, methotrexate, vincristine, actinomycin D, cyclophosphamide, doxorubicin, dacarbazine, bleomycin, or a combination of these drugs. 2 Shon et al 9 treated a patient with ifosfamide, doxorubicin, and paclitaxel after surgery, which seemed to prolong survival by a few months.
However, 13 of the 24 patients described in the literature died rapidly despite treatment, as did our case. Among the 11 patients who were alive at the time of publication, 3 have recurred. Patient age does not seem to be correlated with poor prognosis.
Among the known five reported pediatric cases of angiosarcoma, only our patient received chemotherapy alone, because the tumor was inoperable. All other cases underwent surgery. Two patients survived the follow-up, which was short. Our patient died despite a short delay in diagnosis, which does not seem to influence survival (Table 2) .
Locoregional chemotherapies (isolated limb perfusion, limb infusion, and electrochemotherapy) have been used to treat multifocal cutaneous tumors, but only in adult patients who developed angiosarcoma in the context of a chronic acquired lymphedema after mastectomy.
12
Other systemic adjuvant therapies such as nab-paclitaxel, bevacizumab, and pazopanib have been used as adjuvant treatment for cutaneous angiosarcoma. 13 Experience of their use in children, as well as their efficacy or availability for pediatric patients, is limited.
They were not used to treat this patient.
Several forms of immunotherapy have been tried in the past:
recombinant IL2 and more recently the PD-1 inhibitor pembrolizumab, which was successful in a recent case report. 13 Sirolimus is an immunosuppressive drug most frequently used for kidney transplant recipients. It inhibits the "mammalian target of rapamycin" (mTOR), which gives rise to antiangiogenic and antiproliferative properties. It is used to treat several types of cancers, particularly renal cell carcinoma and Kaposi sarcoma. Sirolimus is emerging as a potential treatment for lymphatic, venous, and combined malformations and chronic recurrent chylothorax that is resistant to conventional treatment. 14 Our patient responded well to sirolimus in terms of resolution of chylothorax.
As an immunosuppressive agent, sirolimus treatment is associated with an increased risk of infection, malignant skin tumors, and lymphoma. Sarcoma as adverse effect of sirolimus has never been reported. 15 Whether sirolimus treatment at such a small dosage and for such a short duration could have accelerated the occurrence of angiosarcoma in our patient remains unresolved.
In conclusion, angiosarcoma is a rare but often fatal complication of congenital lymphedema. It should be suspected when cutaneous lesions start to develop on a lymphedemic limb or area. Surgical resection remains the treatment of choice whenever possible. Chemotherapy and radiation therapy have not proved their efficacy.
Without possible complete surgical resection, most patients die within 5-8 months after diagnosis.
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